Aldeyra Therapeutics to Host Conference Call & Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Tri...
December 02 2019 - 4:01PM
Business Wire
Event scheduled for 8:00 a.m. ET Tuesday,
December 3, 2019
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a
conference call and webcast at 8:00 a.m. ET Tuesday, December 3,
2019, to provide top-line results from Part 1 of the adaptive Phase
3 RENEW Trial of topical ocular reproxalap in patients with dry eye
disease.
The dial-in numbers are (866) 211-4098 for domestic callers and
(647) 689-6613 for international callers. The Conference ID is
1592481. A live audio webcast of the conference call will also be
available on the Investor Relations section of the Aldeyra
Therapeutics website at https://ir.aldeyra.com. Presentation slides
will be available on the investor relations page approximately 30
minutes prior to the start of the conference call and webcast.
After the live webcast, the event will remain archived on the
Aldeyra Therapeutics website for one year.
About Aldeyra Therapeutics Aldeyra Therapeutics is a
biotechnology company devoted to developing and commercializing
next-generation medicines to improve the lives of patients with
immune-mediated diseases. Aldeyra's lead investigational drug
product candidates are potential first-in-class treatments in
development for dry eye disease, allergic conjunctivitis,
proliferative vitreoretinopathy, and Sj�gren-Larsson Syndrome. The
company is also developing other product candidates for retinal and
systemic inflammatory diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191202005925/en/
Corporate Contact: David McMullin Aldeyra Therapeutics,
Inc. 781-761-4904 ext. 218 dmcmullin@aldeyra.com Investor &
Media Contact: Scott Solomon Sharon Merrill Associates, Inc.
617-542-5300 ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Sep 2023 to Sep 2024